Winter Park, Florida--(Newsfile Corp. - March 3, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare innovation, proudly announces a major milestone for its new subsidiary, Adia Labs LLC: the FDA has accepted the registration of Adia Vita. This acceptance reflects Adia Labs' notification to the FDA that it will be storing and distributing its premier stem cell product, Adia Vita, to doctors and clinics nationwide, broadening access to cutting-edge regenerative medicine and significantly increasing revenue potential.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/242494_adia1.jpg
Adia Labs is thrilled to introduce Adia Vita, a top-tier product featuring umbilical cord stem cells with a minimum of 100 million viable cells and 3 trillion exosomes per unit. For people unfamiliar with regenerative medicine, stem cell therapies-such as those provided by Adia Med-usually cost between $15,000 and $35,000 per treatment because of their cutting-edge technology and life-changing benefits. However, Adia Med stands out by offering a superior product at a reduced price, driving rapid client growth and making these therapies more accessible. With the FDA's acceptance of this registration, Adia Labs is poised to bring Adia Vita nationwide, supporting clinical research and delivering therapeutic options for a variety of health conditions.
"Registering Adia Vita with the FDA marks a game-changing moment for us," said Larry Powalisz, CEO of ADIA Nutrition. "We're deeply grateful to the FDA for their timely and cooperative efforts in making this registration possible so quickly. This milestone allows us to reach a vast network of doctors and clinics across the country, offering a high-quality, cost-effective solution that accelerates client growth. We're excited to lead the charge in making advanced patient care more affordable and widespread." Powalisz added, "As of this moment, we are open for business on this front, and we invite any and all medical professionals across the U.S. to give us a call at 321-788-0850 to explore how Adia Vita can enhance their practice."
This FDA registration empowers Adia Labs to expand its reach, connecting healthcare providers nationwide with Adia Vita. By offering a premium product at a lower cost than the typical $15,000-$35,000 range, Adia Med is not only enhancing patient care but also fueling innovation. Doctors gain access to powerful tools for research and trials, potentially paving the way for new regenerative medicine breakthroughs, all while Adia Labs drives advancements in stem cell and exosome applications.
Adia Labs looks forward to rolling out Adia Vita, bringing hope and affordable, high-quality treatment options to patients battling a wide range of health challenges.
For any questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242494
SOURCE: Adia Nutrition Inc.
